Tauriga Sciences Inc (fka TAUG)

[Blackcat7717]

http://immunovativetherapies.webs.com/apps/blog/

Dr. Michael Har-Noy and Immunovative Therapies Develop Unique Cancer Drugs
Posted by anonymous on July 13, 2013 at 3:55 AM comments (0)

Physicianshave been largely unsuccessful in treating patients with metastatic cancer.Medical scientists have made significant advances in early cancer diagnosis andprevention in the past two decades, but they have made relatively few inroadsin treating advanced malignant disease.

The principle problem with current cancer therapies is that they usually cannoteradicate every cancer cell. Furthermore, as in the case of chemotherapy andradiation, they are often very toxic to the body and have unacceptable sideeffects. A young, daring biotech company named Immunovative Therapies Ltd.,founded by Dr. Michael Har-Noy, is hoping to vastly improve the way cancer istreated. Immunovative Therapies is now testing groundbreaking drugs that enableone’s own immune system to kill metastatic cells.

Dr.Michael Har-Noy, founder and CEO of Immunovative Therapies,describes their flagship product, AlloStim™, as a biological drug synthesizedfrom precursors found in the circulation of a normal donor. These precursorsare then purified, differentiated, expanded, and then frozen untilneeded. When infused into a cancer patient’s blood, these unique cellscreate an inflammatory environment which disarms tumor avoidancemechanisms. Because AlloStim™ cells are intentionally mis-matched and areseen by the host as foreign, the patient’s own immune system “wakes up” to thesedanger signals and is able to both reject the AlloStim™ cells and kill thetumor cells.

Dr.Michael Har-Noy, using this patented “Mirror EffectTM” described above, hasessentially produced the tumor-killing effect of a successful allogeneic bonemarrow transplant without exposing the patient to the lethal problem of graftversus host disease.

Preliminary Phase I/II datashows that AlloStim™ has a remarkable anti-tumor effect across a wide varietyof metastatic cancers. A Phase II/III trial of AlloStim™ in the treatment ofmetastatic breast cancer will hopefully be under way soon in Thailand. Withtheir unique biologic drugs, Immunovative Therapies and Dr. Michael Har-Noy may be on the verge of creating an entire new field ofoncology.

Dr. Michael Har-Noy of Immunovative Therapies, Changing The Way Cancer Is Treated
Posted by anonymous on July 4, 2013 at 6:10 AM comments (0)

Over the last few decades, medicine hasmade tremendous strides in the treatment of infectious disease, cardiovascularillness, and other life-threatening conditions. However, most metastatic canceris treated today with similar methods that were used twenty years ago, namely acombination of surgery, chemotherapy, and radiation. Aside from sporadic use ofmonoclonal antibodies and individualized cancer vaccines, cancer therapy hasnot advanced significantly in recent years.

Immunovative Therapies Ltd., a small,relatively new biotech company in Israel, is using a novel approach to treatmetastatic tumors. Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies,is developing unique drugs that “wake-up” a patient’s immune system and enableit to attack and kill metastatic cells. Dr. Michael Har-Noy’s work may usher ina whole new era of cancer therapy.

Dr. Michael Har-Noy, a world-renowned andrecognized immunologist and scientist, spent many years at Hadassah MedicalCenter in Israel studying bone marrow transplant patients and defining theimmunologic characteristics of successful transplant patients that did notdevelop graft versus host disease. At Immunovative Therapies, Dr. MichaelHar-Noy has used this information to formulate complex cellular-based compoundsthat, when administered to a cancer patient, provoke the patient’s own immunesystem to attack the administered drug and in the process, attack the tumor aswell.

At Immunovative Therapies, Dr. MichaelHar-Noy has developed and is testing three prototype compounds; AlloStim™,CryoStim™, and AlloVax™. As opposed to the anti-tumor effect of a bone marrowtransplant, these drugs provoke a tumor-killing immune response that has nopotential for toxicity, as it is the patient’s own immune system, and not aforeign transplant, that initiates the tumor-killing process.

Medical scientists have as yet been unableto consistently stimulate a patient’s immune system to seek out and killcancerous cells. Dr. Michael Har-Noy of Immunovative Therapies appears to havediscovered a way to facilitate this process, and in doing so may sooncompletely change the way cancer is treated.

Blackcat